NCT04764344

Haloperidol for the Treatment of Nausea and Vomiting in the ED

A Single Center, Randomized Controlled Prospective Double-blinded Trial Comparing Haloperidol to Standard Ondansetron Therapy for Control of Nausea and Vomiting in the Emergency Department

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Western Michigan University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

Single center, double-blind, randomized, controlled trial in patients who present to the emergency department (ED) with a chief complaint of nausea or vomiting. A total of 300 patients age 18-55 presenting to the emergency department with chief complaint of nausea or vomiting will be enrolled from February 2021 - February 2022. Patients will be randomized and symptom levels will be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24 hours.

Conditions

• Vomiting
• Nausea
• Abdominal Pain
• Cannabis Use

Interventions

Type	Name	Description
DRUG	Haloperidol	2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP
DRUG	Ondansetron	Ondansetron

Timeline

• Start date: 2021-04-01
• Primary completion: 2023-05-22
• Completion: 2023-05-22
• First posted: 2021-02-21
• Last updated: 2023-06-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study